REVIEW ARTICLE Intraaortic balloon pump in patients with cardiogenic shock complicating myocardial infarction 181 however, its role in cardiogenic shock has been the subject of ongoing debate.
percutaneous coronary intervention (PCI), or supportive care; 5) outcomes: all-cause mortality at hospital discharge, or if not available, the longest period at which mortality was measured is used; intensive care unit (ICU) length of stay (in days); stroke (ischemic or hemorrhagic); limb ischemia; major bleeding (any bleeding that requires transfusion of more than 2 units of blood, or that is associated with hemodynamic instability not explained by conditions other than bleeding).
In duplicate and independently, 2 of 3 reviewers selected articles by examining titles and abstracts and then full texts after identifying potentially relevant articles. We used κ statistic to measure the agreement between reviewers.
18 data collection and quality assessment In duplicate and independently, 2 reviewers (SA and AA) abstracted data on the design, population and demographics, intervention, comparison, and outcomes. WA and BR completed the risk of bias assessment using the Cochrane risk of bias tool. The methodology used to assess quality of evidence is described in detail in the study protocol. 15 For each of the outcomes, we independently rated the quality of evidence and confidence in effect estimates using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.
19 Disagreement was resolved by discussion and consensus. data synthesis and analysis All statistical analyses were conducted using the RevMan 5.1 software (Review Manager [Computer program]. Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011). Using a fixed effect model and applying inverse variance weighting, we combined data from all trials to estimate the pooled risk ratio (RR) and associated 95% confidence intervals (CIs). The fixed effect model is probably a more conservative approach than the random effects model when a large dominating study is included in the analysis. 20 We conducted the test for subgroup interaction using a test for heterogeneity between the subgroups of interest. The I 2 statistic and P values were calculated for each subgroup interaction test.
We assessed statistical heterogeneity using the I² statistic 21 and interpreted substantial heterogeneity as an I² of more than 50%. Although we planned to conduct the Egger test and visually examine funnel plots, we could not reliably assess for publication bias owing to a small number of included trials.
Results Trial identification Our initial search identified 244 citations, of which 10 full-text articles were assessed for eligibility, and after the application of eligibility criteria, 6 articles were excluded (FIguRE 1). Four RCTs met the eligibility criteria and were included in the quantitative and qualitative syntheses.
3,22-24 One trial was published in Spanish, and a Spanish-speaking reviewer completed data abstraction. 24 The agreement of IABP on coronary perfusion is variable with some studies finding little or no change in coronary blood flow, 4-6 while others reporting a significant increase. 6-8 Subsequently, rapid balloon deflation during systole reduces aortic volume (afterload) by creating a vacuum-like effect. These effects are variable and may depend on the volume of the balloon, position in the aorta, heart rate, rhythm, and other factors. 7 The desired hemodynamic effects of IABP include a reduction in systolic blood pressure and an increase in aortic diastolic pressure, which ultimately improves coronary blood flow. The net result is lower heart rate and pulmonary capillary wedge pressure, and higher cardiac output. 7 Registry-based observational studies suggested that the use of IABP may improve hemodynamics in patients with cardiogenic shock and acute MI. 9, 10 A Cochrane review by Unverzagt et al. 11 included 3 randomized controlled trials (RCTs) comparing the use of IABP to standard of care. Given the relatively small sample size of included trials (190 patients), the results were imprecise to draw firm conclusions. Subsequently, a larger RCT (IABP SHOCK II) showed no effect on 30-day mortality when examining the effect of IABP. 3 International clinical practice guidelines recommend the use of IABP in the management of patients with cardiogenic shock caused by acute MI. 12,13 In the view of the recently published literature and the importance of this topic, a comprehensive systematic review is required to summarize and assess the quality of the existing evidence.
Methods study protocol We registered the study protocol in the PROSPERO international register of systematic reviews (PROSPERO 2014. CRD42014007056).
14 Subsequently, we published a study protocol that described in more detail our inclusion criteria, study methodology, quality assessment, and analysis plan. 15 We adhered to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines (Supplementary material online, Table S1 ). 16 search strategy We searched the EMBASE, MED-LINE, and CENTRAL databases from inception to November 2014. The search strategy is summarized in Supplementary material online, Table S2 . We searched conferences and proceedings utilizing search engine provided by the McMaster University online library (PapersFirst). 17 We did not apply language or date restrictions.
Inclusion criteria Eligibility criteria included all of the following: 1) design: parallel group RCTs (crossover or pseudorandomized trials were not eligible); 2) population: adult patients with cardiogenic shock complicating acute MI; 3) intervention: IABP; studies that examined the effects of other mechanical support devices were excluded; 4) comparator: usual care including any or a combination of the following: fibrinolysis, Risk of bias Using the Cochrane risk of bias tool, 3 trials were judged to be at a high risk of bias, which is primarily due to a lack of blinding. As the adverse event outcomes were not based on clear criteria, we judged the risk of performance and ascertainment biases to be high for these outcomes. One trial was determined to be at a low risk of bias despite the lack of blinding. 3 In this trial, the outcomes of interest were rigorously defined; hence, we felt that the assessment and adjudication of the outcomes are less likely to be influenced by the lack of blinding. Upon evaluating mortality outcome, we assumed that the lack of blinding is unlikely to increase the risk of performance or ascertainment biases. Accordingly, we determined the risk of bias to be low for the mortality outcome across all trials. Finally, owing to a lack of information, we could not reliably assess the randomization method or concealment in 1 trial. 24 The details and individual components of the risk of bias are shown in Supplementary material online, Figure S1 .
Pooled outcome A total of 4 RCTs (735 patients) reported mortality as an outcome. 3,22-24 Only 1 trial reported hospital mortality.
23 Two trials reported mortality at 30 days, 3,22 and 1 trial did not specify the time at which mortality was measured. 24 The use of IABP did not reduce the risk of death when compared with usual care (RR, 0.94; 95% CI, 0.79-1.13; P = 0.52; I 2 = 0%; moderate confidence; FIguRE 2).
Two RCTs 3,23 with a total of 638 patients reported the ICU length of stay. However, given the large unexplained statistical heterogeneity (I 2 = 71%), we did not report pooled estimates. The ICU length of stay was not significantly different in both trials (mean difference [MD], 0.00 days; 95% CI, -0.42 to 0.42; P = 1.00) 3 and (MD, -6.00 days; 95% CI, -12 to 0.02; P = 0.05). 23 Reinfarction was only reported in 1 trial; the use of IABP did not reduce the risk of reinfarction during hospital stay (RR, 2.24; 95% CI, 0.70-7.18; P = 0.16).
3
Adverse events Three trials with 660 patients reported stroke, limb ischemia, and bleeding outcomes. Overall, the use of IABP was not associated with a statistically significant increase in the risk of stroke (RR, 0.77; 95% CI, 0.22-2.69; P = 0.68, I 2 = 48%; very low confidence), limb ischemia (RR, 1.24; 95% CI, 0.59-2.59; P = 0.58; I 2 = 0%; low confidence), or major bleeding (RR, 0.76; 95% CI, 0.34-1.72; P = 0.52; low confidence) (FIguRE 2). Of note, the event rate was low for all 3 outcomes ( subgroup analyses We defined all subgroup analyses a priori in our published protocol;
15 however, the lack of data and a small number of studies limited our ability to assess subgroup differences. The results are summarized in FIguRE 3.
on eligible studies after full-text assessment was perfect (κ = 1.0).
Characteristics of studies The characteristics of the included trials are presented in TAbLE 1. The trials included adult patients with cardiogenic shock secondary to acute MI. Anterior MI was the cause in 55% of all randomized patients (range, 42%-77%). The definition of cardiogenic shock was consistent across the included studies, but not identical. One trial mandated the use of pulmonary artery catheter measurements to diagnose cardiogenic shock, 24 while other trials did not require them as eligibility criteria. In the IABP-SHOCK II trial, 3 the mean age of participants was marginally higher than in the other trials (TAbLE 1). One trial used fibrinolysis for all randomized patients, and only 38.6% of participants underwent PCI.
22 Although a standardized protocol for administering the drugs was provided, the choice of fibrinolytic agent was left to the discretion of the treating physician. The majority of patients (>90%) received PCI in the other 3 trials.
3,23,24 In addition, all patients received aspirin and an anticoagulation agent. In the largest trial (IABP-SHOCK II), IABP was inserted either before or immediately after PCI. One-to-one electrocardiographic triggering was used as the initial setting, and this ratio was maintained until there was sustained hemodynamic stabilization. The description of the IABP intervention in other trials is summarized separately in Supplementary material online, Table S3 .
In all trials, crossover to IABP was allowed if patients in the control group developed mechanical complications (eg, ventricular septal defect or papillary muscle rupture). discussion The findings from this meta-analysis are consistent with the results of the most recent trial.
3 The use of IABP is not associated with a significant reduction in mortality in patients with cardiogenic shock secondary to acute MI. Furthermore, the risk of stroke, limb ischemia, and major bleeding was not significantly higher with IABP use.
These findings are based on combining the results of 4 RCTs.
3,22-24 While the previous systematic review also suggested no mortality benefit, the results were limited by imprecision and low quality of evidence. In particular, that systematic sensitivity analyses All sensitivity analyses were specified a priori in the study protocol.
15 Using random-effects model did not significantly change the results for each of the outcomes. No eligible studies in an abstract form were identified; hence, we did not proceed with the second analysis. When excluding studies at a high risk of bias, only a single study was included;
3 however, the results did not change significantly. We decided to conduct a post hoc analysis excluding the study by Arias et al. 24 due to doubts about the randomization methods; however, this did not alter the results (RR, 0.96; 95% CI 0.80-1.16; P = 0.69; I 2 = 0%).
Quality of evidence Using the GRADE approach, we judged the quality of evidence for the mortality outcome to be moderate (moderate confidence), mainly owing to concerns about imprecision. We lowered the quality of evidence for 
given the benefit shown by observational studies, 9 device availability, and operator familiarity. In a meta-analysis of RCTs by Krischan et al., 9 which included patients with acute MI without cardiogenic shock, the use of IABP did not reduce mortality at 30 days. However, they found higher rates of bleeding and ischemic complications, which is not shown in our analysis.
In view of our results, it is important to understand whether the lack of mortality benefit is related to the intervention, population, or other factors. Shiedt et al. 6 have shown that the use of IABP decreases the mean systolic and diastolic pressure by 25% and 35%, respectively. In addition, the use of other hemodynamic support devices failed to show mortality benefit over IABP.
11
Therefore, it is plausible to assume that it is not a device performance failure that led to neutral results. Reversing hemodynamic derangements is a crucial step in managing shock; however, other factors are also of great importance. First, the timing of the intervention in relation to the onset of shock and irreversible organ damage (ischemic time). Applying reperfusion strategy with PCI (as a comparable analogy), a lowering benefit is observed with longer ischemic time; in addition, desirable effects might be lost or revered (cause harm) when performed late. 25 While in most cases the onset of myocardial ischemia is heralded by symptoms, the onset of shock is usually ambiguous and can only be retrospectively estimated. An observational study by Abdelwahhab et al.
26
demonstrated benefit with using IABP before PCI as opposed to after PCI, which could be hypothesis-generating. Unfortunately, due to the lack of data, we were not able to conduct a subgroup analysis by timing of PCI use.
Organ injury after ischemia-reperfusion is a well-established theory. 27 It is known to trigger inflammation and systemic inflammatory response syndrome that could result in organ dysfunction independent of ischemia.
27 It is not known whether this mechanism could have any influence on shock resuscitative strategy or targets.
Whether the lack of related benefit is related to the mechanistic properties of the device or to the population in which it was applied remains unclear. This certainly draws our attention to studies that investigated the efficacy of other hemodynamic support devices (eg, left ventricular assist device) and failed to show mortality benefit. 11 Despite the popularity of using IABP in the treatment of patients with cardiogenic shock, our meta-analysis showed that it does not improve patient-important outcomes (ie, mortality). Strengths of our systematic review include adherence to a prepublished study protocol, comprehensive search strategy, inclusion of RCTs rather than observational studies, adherence to by published RCTs. Second, the lack of some subgroup data in published trials limited our ability to conduct all subgroup analyses. Third, although we included only RCTs, 1 trial was published in Spanish and did not describe the randomization method 24 ; in addition, the number of patients was not balanced in the 2 groups, which makes us question the randomization method used. For this purpose, we conducted a post hoc sensitivity analysis excluding the data of this study, but the results remained similar.
All trials included patients with evidence of acute MI and objective clinical and hemodynamic the PRISMA guidelines, and the use of GRADE methodology to assess the quality of evidence.
However, there are key limitations of the current literature that are worth discussing. First, owing to a small sample size and low event rate in the included RCTs, we were not able to reliably assess the risks of complications (harm). Hence, the quality of evidence for these outcomes was very low or low. A meta-analysis of observational studies reported a higher risk of adverse events with the use of IABP, including a higher risk of bleeding and ischemic complications. 9 We have low confidence in the estimates of adverse events provided of evidence suggests that the use of IABP is not associated with a higher risk of complications.
parameters of cardiogenic shock; the generalizability of the results should be limited to this population. While the use of IABP may be safe, there is no evidence to support its routine use in patients presenting with acute MI complicated by cardiogenic shock. Literature on high-risk patients undergoing coronary artery bypass grafting showed that the use of IABP may be of benefit in female patients with comorbidities.
28 It is unclear whether IABP has a beneficial effect in a specific subgroup, namely, in patients presenting with cardiogenic shock. Perhaps future studies should explore the potential of benefit in specific subgroups.
The results of our meta-analysis should be interpreted with caution, particularly when dealing with refractory cardiogenic shock or high-risk groups. None of the trials used IABP primarily as a rescue therapy for patients with cardiogenic shock and refractory hypotension. The generalizability of the results to this population is limited by indirectness. For instance, in our analysis, the pooled mortality rate in the control group was 40.3% (143 deaths out of 355 patients), which is lower than what is described in previous studies.
6 Furthermore, only 27% of the patients in the largest trial (IABP-SHOCK II) had a systolic blood pressure of less than 80 mmHg. On the contrary, it is challenging to conduct research (especially RCTs) when dealing with emergent and life-threatening conditions. Therefore, clinical decision making should be individualized, particularly when dealing with high-risk groups. An individual patient data meta-analysis or an RCT focusing on a high-risk population will be of great value.
Conclusions
Moderate quality of evidence suggests that the use of IABP does not improve survival in patients with cardiogenic shock and acute MI. However, the results should not be used to guide clinical decision when dealing with a highrisk group or patients with refractory shock, as this population was not represented in the previously published RCTs. Low and very low quality of evidence suggests that the use of IABP is not associated with significant harm; however, these findings should be interpreted with caution as the included trials are underpowered to show any statistically significant difference. Larger trials with a homogenous population and cointerventions are required to confirm these observations.
Key messages
The key messages of our paper are as follows: 1) prior systematic reviews on the use of IABP in patients with cardiogenic shock were limited by imprecision and quality of evidence; 2) a recent large RCT 3 suggested that the use of IABP in this population does not improve survival; 3) this systematic review and meta-analysis of RCTs suggests that the use of IABP in patients with cardiogenic shock complicating myocardial ischemia does not improve mortality (moderate quality of evidence); and 4) low and very low quality 
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METHODS
Protocol and registration 5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.
Eligibility criteria 6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
5
Information sources 7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies)
in the search and date last searched.
Search 8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
Study selection 9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
Data collection process 10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.
6
Data items 11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
7
Risk of bias in individual studies 12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.
8
Summary measures 13 State the principal summary measures (e.g., risk ratio, difference in means).
9,10
Synthesis of results 14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I
2 ) for each meta-analysis. Additional analyses 16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.
RESULTS
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.
7
Study characteristics 18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.
7,8
Risk of bias within studies 19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).
8
Results of individual studies 20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. Initial rate at 1:1 for 48 hours, weaning was done gradually over 12 hours.
In patients who remained hypotensive (SBP<90mmHg) or developed ischemia the IABP was continued.
Prondzinsky 2010 A 40 mL balloon IABP (IABP System 97, Datacope; Fairfield, NJ) was inserted immediately after PCI.
IABP device was continued for a minimum of 48 hrs.
Rate and weaning strategy was not described.
Thiele 2012 IABP was inserted either before or immediately after PCI, 1:1 electrocardiographic triggering was used as initial the setting, this ratio was maintained until there was sustained hemodynamic stabilization.
IABP: intra-aortic balloon pump; PCI: primary percutaneous intervention; SBP: systolic blood pressure.
Figure S1. Summary of Risk of Bias
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2 ) for each meta-analysis. 
DISCUSSION
Summary of evidence 24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).
10,11,12
Limitations 25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). Initial rate at 1:1 for 48 hours, weaning was done gradually over 12 hours.
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